Aeglea a clinical-stage biotechnology company that engineers next generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency and in combination with an immune checkpoint inhibitor for small cell lung cancer. Aeglea has two pipeline programs in IND-enabling studies for Homocystinuria and Cystinuria and an active discovery pipeline. Source
No articles found.
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company ...
Iterum Therapeutics plc is an Ireland-based cli...
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...
MacroGenics is a clinical-stage biopharmaceutic...
PhaseBio is a clinical-stage biopharmaceutical company focused on the development ...
PhaseBio is a clinical-stage biopharmaceutical ...
Champions Oncology, Inc. is engaged in the development of advanced technology solu...
Champions Oncology, Inc. is engaged in the deve...
Coherus BioSciences is a leading biosimilar company that develops and commercializ...
Coherus BioSciences is a leading biosimilar com...
Join the National Investor Network and get the latest information with your interests in mind.